Business
Prothena Reports First Quarter 2025 Financial Results and Business Highlights
DUBLIN, May 08, 2025--Prothena today reported financial results for the first quarter of 2025 and provided business highlights.
About this update from Prothena Corporation Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3612,"height":1160,"url":"https://media.zenfs.com/en/business-wire.com/e5b097d0df25a804705e336b848b2c7b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5KEYnF4jv5TC0NETCSLB_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e5b097d0df25a804705e336b848b2c7b","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/BWlhLjBWJS1_MowJZxnaVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e5b097d0df25a804705e336b848b2c7b","width":1200,"height":385}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Net cash used in operating and investing activities was $53.4 million in the first quarter of 2025; quarter-end cash and restricted cash position was $418.8 million","length":164,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Topline results expected in 2Q 2025 from the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo Stage IV AL amyloidosis being conducted under a SPA agreement with the FDA with a primary endpoint of all-cause mortality (time-to-event) at a statistical significance level of 0.10","length":308,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Multiple clinical readouts for PRX012, a potential single-injection once-monthly subcutaneous treatment for millions of patients with presymptomatic or early symptomatic Alzheimer’s disease, expected starting around mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials","length":307,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Results from the Phase 2b PADOVA clinical trial of prasinezumab in patients with early Parkinson’s disease presented at AD/PD 2025 by partner Roche; the totality of the data presented suggest a possible benefit in early-stage Parkinson’s disease; Roche is further evaluating study data and will work together with health authorities to determine next steps around mid-year 2025","length":377,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1156,"olType":false},{"type":"text","content":"DUBLIN, May 08, 2025--(BUSINESS WIRE)--Prothena Corporation plc...